{"classes":[{"categories":[{"measurements":[{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.","groupId":"OG000","lowerLimit":"23.8","upperLimit":"NA","value":"39.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"For participants who demonstrated a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult participants received pembrolizumab (MK-3475) 200 mg or pediatric participants received 2 mg/kg (up to 200 mg) on Day 1 Q3W IV for up to 35 administrations (approximately 2 years).","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all allocated participants who received at least 1 dose of study treatment, and who experienced a confirmed CR or confirmed PR.","reportingStatus":"POSTED","timeFrame":"Up to ~58 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}